CSL Archives - Page 3 of 3

CSL Promises Another Big Year

August 14, 2014 - by Glenn Dyer

More of the same from the past couple of years is promised for the coming year from Australia’s global pharmaceutical giant, CSL – a solid profit rise, higher dividend, with another buyback also possible.

Markets

CSL Optimistic Of Continued High Demand

February 12, 2014 - by Juliana Roadley

Blood and plasma products and vaccines maker CSL (CSL) reported its half year numbers today. The CSL Group reported a 3.7% rise in sales with total revenue (includes royalties) increasing by 4.8% to US$2.574 billion.

CSL Reveal New $950 Million Buyback

October 17, 2013 - by Glenn Dyer

Shares in CSL closed up 1.3% yesterday at $66.26 as shareholders showed their appreciation of the company’s 7th share buyback which could total up to $950 million.

CSL Posts 19% Net Profit Boost

August 15, 2013 - by Glenn Dyer

CSL was another major company whose shares were sold down yesterday, despite the group reporting a very solid full year profit and a higher dividend.

Profits: Strong Dollar Hits CSL Interim, Again

February 17, 2011 - by Glenn Dyer

CSL has again seen profits hit by the strong Australian dollar, yesterday forecasting a 10% fall in full year earnings based on current exchange rates.

Profits; CSL Down Despite New Buyback, Higher Payout

August 19, 2010 - by Glenn Dyer

Australia’s biggest drug company, CSL Ltd, seems to have run out of ideas for new investment, so it is going for another buy back offer to shareholders of up to $900 million.

CSL’s Trifecta; Profit, Dividend, Shares Up

February 18, 2010 - by Glenn Dyer

Shares in CSL Ltd, the country’s major pharmaceutical group, rose strong yesterday after a bullish outlook from the company and CEO Brian McNamee.

CSL shares went for a run Tuesday, jumping $1 (adding $183 million to the value of the company), before fading to end the day square, and then continued lower yesterday.